Mebutamate
Mebutamate is a carbamate derivative used as an anxiolytic drug. It is similar in structure and function to barbiturates and is generally considered part of the group of sedative-hypnotic drugs. Mebutamate is primarily used to treat short-term anxiety and tension, and it is marketed under the brand names Equanil and Miltown.
History[edit]
Mebutamate was first synthesized in the 1950s and quickly gained popularity as a treatment for anxiety and tension. It was one of the first drugs of its kind, predating the development of benzodiazepines, which are now more commonly used for these purposes.
Pharmacology[edit]
Mebutamate acts on the GABA receptor, enhancing the effect of the neurotransmitter GABA in the brain. This results in a calming effect, reducing feelings of anxiety and tension. The drug is rapidly absorbed in the gastrointestinal tract and is metabolized in the liver.
Side Effects[edit]
Common side effects of mebutamate include drowsiness, dizziness, and weakness. More serious side effects can include confusion, slow heart rate, and difficulty breathing. Long-term use of mebutamate can lead to physical dependence and withdrawal symptoms if the drug is abruptly discontinued.
Legal Status[edit]
In the United States, mebutamate is classified as a Schedule IV controlled substance under the Controlled Substances Act. This means it has a low potential for abuse and low risk of dependence.
See Also[edit]
